Compare GSK plc (GSK) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VF Corp — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while VF Corp trades at $17.34 (market cap $6.76B). The key difference: GSK plc is far larger — about 15× VF Corp's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | VFC | |
|---|---|---|
Market Cap | $101.34B | $6.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $21.55 |
52-Week Low | $36.20 | $11.66 |
Enterprise Value | $121.95B | $10.91B |
Dividend Yield | 3.49% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VFC Corporation (VFC) trades at $16.67, down 1.24% on the day, with a bearish technical signal and mixed earnings performance. The company reported a net loss of $189.72M for 2025 despite revenue of $9.50B, though recent quarters Q3 and Q4 2025 beat EPS expectations. Analyst consensus is a 'Buy' with a $19.33 price target, representing a 16% potential upside, while technical indicators show resistance at $17 and support at $16.
The outlook suggests a turnaround opportunity as the company guides toward profitability in 2026 with projected net income of $255M. Key risks include ongoing brand challenges at Vans, high debt levels, and weak consumer confidence. The stock's current valuation at a P/E of 26.94 and P/S of 0.71 presents a value proposition if management successfully executes its recovery plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
